Choose a channel
Check out the different Progress in Mind content channels.
Progress in Mind
Interview with Dr Zagozdzon, Poland on talking to patients about schizophrenia, quality of life and more.
A. We avoid using the term lifelong and usually postpones giving such information until asked or confronted. This is because, at the outset of managing a patient, it is unclear whether or not remission of psychosis is likely to be long-lasting or if the patient is at high risk of persistent symptoms. The first visit is too early to make such a judgement, especially if there are problems with compliance.
A. Initially, the necessity for therapy is emphasised. Such therapy lasts 1 year or longer, depending on the course of the disease.
A. The presence of psychotic symptoms impacts on a patient’s quality of life as do participating in social activities and being in paid employment.
A. We take a holistic approach to patient management. We not only prescribe the most suitable therapy but we work with psychologists to get to know and understand our patients.
A. Neither. Schizophrenia is a heterogeneous disease and looking at it from either perspective doesn’t help us as psychiatrists to choose the most appropriate therapies. More needs to be known about the role that a history of trauma or genetics plays and we really don’t know how neurodevelopmental disorders are brought about.
A. About 30% of patients can improve their relationships.
Our correspondent’s highlights from the symposium are meant as a fair representation of the scientific content presented. The views and opinions expressed on this page do not necessarily reflect those of Otsuka and Lundbeck.